Fonte: PLOS ONE. Unidades: HU, FM
Assuntos: BIOMARCADORES, METABOLISMO, MORTALIDADE, FALÊNCIA RENAL CRÔNICA, GENES, ALBUMINÚRIA
ABNT
TITAN, Silvia M et al. Metabolomics biomarkers and the risk of overall mortality and ESRD in CKD: results from the Progredir Cohort. PLOS ONE, v. 14, n. 3, p. e0213764, 2019Tradução . . Disponível em: https://doi.org/10.1371/journal.pone.0213764. Acesso em: 05 nov. 2024.APA
Titan, S. M., Venturini, G., Padilha, K., Goulart, A. C., Lotufo, P. A., Benseñor, I. M., et al. (2019). Metabolomics biomarkers and the risk of overall mortality and ESRD in CKD: results from the Progredir Cohort. PLOS ONE, 14( 3), e0213764. doi:10.1371/journal.pone.0213764NLM
Titan SM, Venturini G, Padilha K, Goulart AC, Lotufo PA, Benseñor IM, Krieger JE, Thadhani RI, Rhee EP, Pereira AC. Metabolomics biomarkers and the risk of overall mortality and ESRD in CKD: results from the Progredir Cohort [Internet]. PLOS ONE. 2019 ; 14( 3): e0213764.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1371/journal.pone.0213764Vancouver
Titan SM, Venturini G, Padilha K, Goulart AC, Lotufo PA, Benseñor IM, Krieger JE, Thadhani RI, Rhee EP, Pereira AC. Metabolomics biomarkers and the risk of overall mortality and ESRD in CKD: results from the Progredir Cohort [Internet]. PLOS ONE. 2019 ; 14( 3): e0213764.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1371/journal.pone.0213764